Putnam Investments’s Alnylam Pharmaceuticals ALNY Stock Holding History

Putnam Investments’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	$3.26M	Buy	+17,055	New	+$2.91M	﹤0.01%	608
2022 Q4	–	Sell	-72,194	Closed	-$14.4M	–	1136
2022 Q3	$14.4M	Buy	72,194 +43,294	+150%	+$8.26M	0.03%	233
2022 Q2	$4.21M	Buy	+28,900	New	+$4.1M	0.01%	482
2021 Q2	–	Sell	-82,300	Closed	-$11.6M	–	780
2021 Q1	$11.6M	Buy	+82,300	New	+$12.4M	0.02%	350
2020 Q3	–	Sell	-27,541	Closed	-$4.08M	–	826
2020 Q2	$4.08M	Buy	+27,541	New	+$3.71M	0.01%	509
2019 Q3	–	Sell	-80,500	Closed	-$5.84M	–	888
2019 Q2	$5.84M	Buy	+80,500	New	+$6.18M	0.01%	479
2018 Q3	–	Sell	-12,660	Closed	-$1.25M	–	1067
2018 Q2	$1.25M	Buy	+12,660	New	+$1.26M	﹤0.01%	822
2017 Q4	–	Sell	-134,572	Closed	-$15.8M	–	1079
2017 Q3	$15.8M	Buy	+134,572	New	+$11.5M	0.04%	299

Other funds holding ALNY

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Putnam Investments's ALNY Position: Q4 2023 in Review

Putnam Investments opened a new position in Alnylam Pharmaceuticals (ALNY) in Q4 2023: 17,055 shares worth $3.26M. The stake represents ﹤0.01% of the portfolio and ranks #608 among its holdings. This is a return to the name: Putnam Investments previously reported a position in ALNY as recently as Q3 2022.

Putnam Investments first reported a position in ALNY in Q3 2017 and has held it in 8 quarters since. The position peaked at $15.8M in Q3 2017. 499 funds tracked by Wall St. Rank hold ALNY as of Q4 2023.

Putnam Investments held 17,055 shares of Alnylam Pharmaceuticals worth $3.26M as of Q4 2023.
Alnylam Pharmaceuticals was a new Putnam Investments position in Q4 2023.
Alnylam Pharmaceuticals made up ﹤0.01% of Putnam Investments's portfolio in Q4 2023, its #608 holding.
Putnam Investments first reported a position in Alnylam Pharmaceuticals in Q3 2017 and has held it in 8 quarters since.
Putnam Investments's Alnylam Pharmaceuticals position peaked at $15.8M in Q3 2017.
499 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q4 2023.

Based on Putnam Investments's 13F filing for Q4 2023, filed 14 Feb 2024.